72 related articles for article (PubMed ID: 9750525)
21. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer.
Linzer DG; Stock RG; Stone NN; Ratnow R; Ianuzzi C; Unger P
Urology; 1996 Nov; 48(5):757-61. PubMed ID: 8911521
[TBL] [Abstract][Full Text] [Related]
22. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
23. [Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].
Fujimoto H
Nihon Rinsho; 2005 Feb; 63(2):271-8. PubMed ID: 15714978
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
26. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
Civantos F
Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
[TBL] [Abstract][Full Text] [Related]
27. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
[TBL] [Abstract][Full Text] [Related]
29. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
30. [A survey of radical surgery without neoadjuvant therapy for patients with stage B and C prostatic carcinoma].
Matsuzaki J; Kanda F; Watanabe T; Ouchi H; Tsuchiya F; Fukuda M; Satomi Y
Hinyokika Kiyo; 2001 Jan; 47(1):5-10. PubMed ID: 11235223
[TBL] [Abstract][Full Text] [Related]
31. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.
Dalkin BL; Ahmann FR; Nagle R; Johnson CS
J Urol; 1996 Apr; 155(4):1357-60. PubMed ID: 8632574
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
34. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant hormone therapy: the Canadian trials.
Klotz L; Gleave M; Goldenberg SL
Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer.
Stone NN; Stock RG
Mol Urol; 1999; 3(3):239-244. PubMed ID: 10851329
[TBL] [Abstract][Full Text] [Related]
37. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Andros EA; Danesghari F; Crawford ED
Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
[TBL] [Abstract][Full Text] [Related]
39. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
40. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
